Medical Director, Patricia D. and M. Scot Kaufman Cancer Center
Education and Training
1979-1983 B.A., Chemistry, University of Virginia
1984-1988 M.D., Eastern Virginia Medical School
Post Graduate Education and Training
1988-1989 Internship, Internal Medicine, Eastern Virginia Graduate School of Medicine
1989-1992 Residency, Radiation Oncology, University of Maryland (Chief 1992)
1992-1993 ACS Fellowship, Radiation Oncology, University of Maryland
I was born in Seoul, Korea. I immigrated to United States with family at age of 11. We landed in Virginia and I grew up mostly in Northern Virginia until completing professional degree. I grew up in a very strict but supportive environment (my father was a retired Marine Colonel and Deacon at local Southern Baptist church). My ties to Maryland began with the residency and fellowship training at University of Maryland Hospital. Except for a brief two and one half years of teaching assignment at Eastern Virginia Medical School, I have been practicing in the greater Baltimore area for over twenty years. I returned to the University of Maryland in November 2015 as a medical director of Kaufman cancer Center, Department of Radiation Oncology.
I currently reside at Clarksville, Maryland. I have an extremely understanding and supportive wife of 28 years, Jihyun. I have two wonderful daughters, Justine (24) who is a graduate of University of Maryland and currently works for national public relation firm in Washington DC and Jenna (19), who is a freshman at University of Maryland, College Park.
On my free time, I enjoy all sporting events with special avid love for soccer (especially enjoy weekend European Soccer watching on internet/cable with special preference of Premier League action from England) and golf (weekend hacker mostly). I am self-acclaimed “sports Junkie”, trying my best to keep up with modern world of sports.
I feel privileged to be part of University of Maryland Cancer Network. As with many families in United States, personal family experience with cancer has affected my approach to each patient, always remembering a patient focus with individualized special attention, while trying to achieve the most optimal clinical outcome, with compassion and dedication. I am excited about the new cancer care initiatives and committed to continue a “Patient First” attitude in all my interactions.
Cooperative group clinical trials (NRG: RTOG, GOG, NSABP) Intramural clinical trials (Greeenbaum Cancer Center)
Peer-Reviewed Journal Articles
1. The labeling of high affinity sites of antibody with Technetium-99m; Paik CH, Phan LNB, Hong JJ, Eckelman WC, Reba RC; International Journal of Nuclear Medicine and Biology; Vol 12, No. 1, pp. 3-8, 1985.
2. Relative reactivity of DTPA, immunoreactive antibody-DTPA conjugates and non-immunoreactive antibody-DTPA conjugates toward Indium-111; Paik CH, Hong JJ, Ebbert MA, Heald SC, Reba RC, Eckelman WC; Journal of Nuclear Medicine, Vol 26, No. 5; pp. 482-487, 1985.
3. Curved tandem vaginal applicator for the HDR intracavitary afterloading therapy in the postoperative carcinoma of the endometrium; Hong JJ, Kasenter A, El-Mahdi AM; Gammanews, Vol 1, No. 2, pp. 12-13, 1995.
4. Role of adjuvant therapy in malignant chondroid syringoma; Hong JJ, Elmore J, Drachenberg C, Jacobs M, Salazar OM; Journal of Dermatologic Surgery and Oncology, Vol 21, pp. 781-785, 1995.
5. Divergent changes of flow through individual blood vessels upon localized heating; Rhee JG, Eddy HA, Hong JJ, Suntharalingum M, Vaupel PW; Int. J. Hyperthermia, Vol 12, No. 6, pp. 757-769, 1996.
6. High dose rate brachytherapy in prevention of vaginal recurrence in early stage endometrial carcinoma: Preliminary analysis; Hong JJ, Yacoub SF, Blevins JC, Kuban DA, El-Mahdi AM; American Journal of Clinical Oncology, Vol 20, No. 3, pp. 254-258, 1997.
7. An open-label, randomized study to develop a screening tool for functional capacity in anemic subjects with non-myeloid malignancies receiving chemotherapy and darbepoetin alfa; Vadhan-Raj S, Hong JJ, Gregory SA, Terry D, Tomita D, Colowick A; J. Supportive Oncology, Vol 2, supp 2, pp 32-33, 2004.
Endobronchial Brachytherapy. Hong JJ, Godette KD, Suh JH, Oh MC; Flexible Bronchoscopy; second edition; 2003.
1. Two sites of IgG and its F(ab')2 fragment for Tc-99m and biodistributions of Tc-99m labelled F(ab')2 in mice; Paik CH, Hong JJ, Sahami MS, Eckelman WC; American Cancer Society 1985.
2. Optimization of Tc-99m DTPA formation in competition with direct labelling of F(ab')2; Paik CH, Phan LNB, Hong JJ, Eckelman WC, Reba RC; Journal of Labelled Compounds and Radiopharmaceuticals 21(11) pp. 996-998, 1984.
3. Factors influencing radiolabelling of antibody with Indium-111; Paik CH, Hong JJ, Ebbert MA, Eckelman WC, Reba RC; Radiopharmaceutical Chemistry International Meeting, Japan 1984; Journal of Labelled Compounds and Radiopharmaceuticals 21: pp. 1028-1030, 1984.
4. Preparation of a stable Tc-99m complex of F(ab')2-DTPA and its distribution in mice; Paik CH, Sahami MS, Hong JJ, Eckelman WC, Reba RC; Society of Nuclear Medicine Annual Meeting 1984.
5. Heterogeneous development of thermotolerance in RIF-1 multicell spheroids; Rhee JG, Walker EM, Hong JJ, Ordonez JV; Sixth International Congress on Hyperthermic Oncology, April, 1992.
6. Importance of intracellular pH and blood flow in thermal cell killing of tumors; Hong JJ, Rhee JG, Eddy HA, Slawson RG, Salazar OM; Sixth International Congress on Hyperthermic Oncology; April, 1992.
7. Prognostic significance of p53 protein expression in patients with squamous cell carcinoma of the tongue treated with radiation therapy; Sorensen MD, Long JP, Somers KD, Bramhall TC, Hong JJ, Schecter GL, El-Mahdi AM; American Association for Cancer Research; April 23, 1996.
8. Every 2 week Darbepoetin alfa improves fatigue and energy rating scores in cancer patients undergoing chemotherapy; Vadhan-Raj S, Schreiber F, Thomas L, Gandhi J, Hong JJ, Gregory SA, Tomita D, Colowick A; proc. ASCO, May, 2003
9. An open-label, randomized study to develop a screening tool for functional capacity in anemic subjects with non-myeloid malignancies receiving chemotherapy an darbepoetin alfa; Vadhan-Raj S, Hong JJ, Gregory S, Tomita D, Colowick A; Proc ASH, Nov. 2003.
10. Baseline (BL) covariates of response to darbepoetin alfa (DA) every 2 weeks (Q2W) in patients (pts) with chemotherapy-induced anemia (CIA); Vadhan-Raj S, Mirtsching B, Gregory S, Hong JJ, Fessen M, Yao B, Rossi G, Blayney D; Proc. ASCO, May 2004.
Pasrticipation in national and intramural clinical trials.
Community cancer care with special interest in brachytherapy and clinical trial participations
2002 American Cancer Society, Mid-Atlantic Division Regional Volunteer Program of Work
Professional Society Memberships
1990-present Member, American Society of Clinical Oncology
1990-present Member, American Society for Therapeutic Radiology and Oncology
1993-present Member, Mid-Atlantic Society of Radiation Oncology
1993-present Member, American College of Radiation Oncology
1993-present Member, American College of Radiology
1993-present Member, Korean American Medical Association
1997-present Member, Korean American Society for Therapeutic Radiology and Oncology
University of Maryland, Upper Chesapeake Medical Center
2015-present Radiation Safety Committee
2015-present Cancer Program Advisory Board
2015-present Cancer Committee
2015-present Breast Cancer Advisory Board
2015-present Head and Neck Cancer Advisory Board
2016-present Thoracic Oncology Advisory Board
1993-1996 Assistant Professor, Eastern Virginia Medical School
1996-1997 Assistant Professor, UMSOM
2008-2015 Clinical Assistant Professor, Clinical and Experimental Therapeutics, Georgetown University, Lombardi Cancer Center
2015-presetnt Assistant Professor, University of Maryland